GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biomind Labs Inc (OTCPK:BMNDF) » Definitions » FCF Margin %

BMNDF (Biomind Labs) FCF Margin % : 0.00% (As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Biomind Labs FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Biomind Labs's Free Cash Flow for the three months ended in Sep. 2024 was $-0.11 Mil. Biomind Labs's Revenue for the three months ended in Sep. 2024 was $0.00 Mil. Therefore, Biomind Labs's FCF Margin % for the quarter that ended in Sep. 2024 was 0.00%.

As of today, Biomind Labs's current FCF Yield % is -2.29%.

The historical rank and industry rank for Biomind Labs's FCF Margin % or its related term are showing as below:


BMNDF's FCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -129.705
* Ranked among companies with meaningful FCF Margin % only.


Biomind Labs FCF Margin % Historical Data

The historical data trend for Biomind Labs's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomind Labs FCF Margin % Chart

Biomind Labs Annual Data
Trend Dec21 Dec22 Dec23
FCF Margin %
- - -

Biomind Labs Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Biomind Labs's FCF Margin %

For the Biotechnology subindustry, Biomind Labs's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biomind Labs's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biomind Labs's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Biomind Labs's FCF Margin % falls into.


;
;

Biomind Labs FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Biomind Labs's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-0.766/0
= %

Biomind Labs's FCF Margin for the quarter that ended in Sep. 2024 is calculated as

FCF Margin=Free Cash Flow (Q: Sep. 2024 )/Revenue (Q: Sep. 2024 )
=-0.111/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biomind Labs FCF Margin % Related Terms

Thank you for viewing the detailed overview of Biomind Labs's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Biomind Labs Business Description

Traded in Other Exchanges
Address
Camino Saravia s/n, Pando Science and Technology Park, Pando Canelones, Canelones, URY, CP 91.000
Biomind Labs Inc is a biotech Research and Development company aimed at transforming biomedical sciences knowledge from natural psychotropic plants into novel pharmaceutical drugs and nanotech delivery systems for a variety of psychiatric and neurological conditions. Biomind is developing pharmaceutical sole and combined formulations of the main natural psychedelic molecules with the aim of identifying novel pharmaceutical compounds for treating a wide range of therapeutic indications.